小细胞肺癌IC和EP方案化疗随机对照临床研究  

Clinical research of SCLC chemotherapy by IC and EP with random control

作　　者：张志胜[1] 陈凌翔[2] 

机构地区：[1]姜堰市人民医院肿瘤科,江苏姜堰225500 [2]江苏省肿瘤医院肿瘤内科,江苏南京210009

出　　处：《中华肿瘤防治杂志》2012年第15期1180-1183,共4页Chinese Journal of Cancer Prevention and Treatment

摘　　要：目的:探讨伊立替康联合卡铂(IC)与依托泊苷联合顺铂(EP)方案在治疗小细胞肺癌(SCLC)的近期疗效和毒副作用。方法:73例SCLC患者被简单随机法分为2组,分别接受IC(36例)和EP方案(37例)2个周期后,比较有效率、完全缓解率等指标,并评估治疗方案的毒副作用。结果:IC组有效率为58.3%(21/36),完全缓解率为25.0%(9/36);EP组有效率为62.2%(23/37),完全缓解率为21.6%(8/37),两组近期疗效比较差异无统计学意义,P>0.05。在血液系统毒性方面,EP组>Ⅲ度中性粒细胞下降率显著高于IC组,P=0.002 5;血小板下降率、白细胞下降率和贫血率与EP组差异无统计学意义,P值分别为0.960 7、0.077 5和0.150 0。在胃肠道毒副作用方面,IC组>Ⅲ度腹泻发生率与EP组差异无统计学意义,P=0.404 7;在严重呕吐、肝酶升高方面差异无统计学意义,P值分别为0.965 0、0.969 6;在肾毒性方面,2组>Ⅲ度度血尿、BUN和肌酐升高率差异无统计学意义,P值均>0.05。周围神经炎、静脉炎和脱发均少见。2组均无治疗相关性死亡。结论:IC和EP方案近期疗效及安全性无显著差异,在临床应用中可以根据患者自身情况选择使用。OBJECTIVE： To compare the effectiveness and toxicity effect of combine chemotherapy regimen of irino- tecan plus carboplatin （IC） and EP regimen in the treatment of SCLC. METHORDS： Seventy-three defined SCLC patients were randomly divided into IC group （n=36） and EP group （n=37）. All the patients were given more than two chemo- therapy cycles and compare the rate of CR,PR,SD,PD, RR of the two groups. RESULTS：The overall response rate was 58.3% in IC group and 62.2% in EP group. The complete remission was 25.0%（9/36） in IC group and 21.6%（8/37） in EP group. There was no significant difference in the response rate between the two groups （P〉0.05）. In terms of hemat- logic toxicity, neutropenia were more frequent in EP group than those in IC group （P=0. 002 5） but there was no signifi cant difference in thrombocytopenia rate （P= 0. 960 7）, leucopenia （P= 0. 150 0） and anemia rate（P= 0. 077 5）. In terms of toxicity in the gastrointestinal tract there was no significant difference in 〉Ⅲ degree diarrhea incidence （P = 0. 404 7）, severe vomiting （P=0. 965 0）, elevated liver enzymes （P=0.969 6） between the two groups. In nephrotoxici ty there was no significant difference in 〉Ⅲ degree of hematuria, BUN and creatinine increase rate. Peripheral neuritis, phlebitis, baldness was rarely observed. There was no chemotherapy-related death. CONCLUSION： IC regimen was e qually effective and safe for SCLC comparing with EP regimen, we can choose them it for clinical application.

关 键 词：癌 小细胞肺 顺铂 药物疗法 联合 随机对照试验 

分 类 号：R734.2[医药卫生—肿瘤]